Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dabrafenib + trametinib + panitumumab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
The combination of **dabrafenib**, **trametinib**, and **panitumumab** is an investigational regimen targeting advanced or metastatic BRAF V600E-mutant colorectal cancer. Dabrafenib is a small-molecule inhibitor of mutant BRAF kinase, trametinib is a small-molecule inhibitor of MEK1/2 (part of the MAPK pathway), and panitumumab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR). The rationale for this triplet therapy is to block compensatory feedback reactivation of the MAPK pathway in BRAF-mutant colorectal tumors that are resistant to BRAF inhibition alone. This combination has been studied in phase I/II trials, demonstrating antitumor activity and a safety profile characterized chiefly by dermatologic, gastrointestinal, and constitutional side effects[1][3][8].
- Brand names
- Tafinlar + Mekinist + Vectibix
- Other names
- D+T+P
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)BRAF V600EMEK1 (Dual specificity mitogen-activated protein kinase kinase 1)
Beyond the preview
Go deeper on dabrafenib + trametinib + panitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dabrafenib + trametinib + panitumumab.